Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepa Jagadeesh

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Blood Advances|January 4, 2018
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HLMonika Pilichowska, Stefania Pittaluga, Judith A Ferry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 StudyBenoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
British Journal of Haematology|December 22, 2018
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphomaBrian T Hill, Loretta Nastoupil, Allison M Winter, et al.
Blood Cancer Journal|June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Susan M Geyer, Levi Pederson, et al.
Blood Advances|September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent eraSanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021Steven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Blood Advances|January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN StudyKrish Patel, Julie M Vose, Sunita D Nasta, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Blood Advances|January 4, 2018
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HLMonika Pilichowska, Stefania Pittaluga, Judith A Ferry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 StudyBenoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
British Journal of Haematology|December 22, 2018
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphomaBrian T Hill, Loretta Nastoupil, Allison M Winter, et al.
Blood Cancer Journal|June 24, 2026
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Susan M Geyer, Levi Pederson, et al.
Blood Advances|September 20, 2023
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent eraSanjal H Desai, Michael A Spinner, Andrew M Evens, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021Steven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Blood Advances|January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN StudyKrish Patel, Julie M Vose, Sunita D Nasta, et al.
Pageof 10